Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xingshen Huayu dripping pill is a Traditional Chinese Medicine (TCM) formulation developed by the Beijing University of Chinese Medicine Pharmaceutical Factory. It is specifically designed for the treatment of acute ischemic stroke (cerebral infarction), particularly in patients diagnosed with the 'phlegm-heat and blood stasis' syndrome according to TCM principles. The medication is delivered in the form of a dripping pill, a dosage form intended to enhance the solubility and absorption of its botanical constituents. It has undergone Phase II clinical evaluation in China to investigate its safety and efficacy in improving neurological outcomes when administered within the acute window (7 days) of stroke onset.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xingshen Huayu dripping pill.